https://www.selleckchem.com/products/mrtx1719.html
Faced with limited and inadequate treatment options for patients with advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC), researchers have turned toward, with the support of promising clinical trials, anti-PD-1/anti-PD-L1 antibody therapy. But there are also different clinical trial results. To better assess its efficacy and safety, we integrated data from 13 eligible studies for a systematic review and meta-analysis. To comprehensively evaluate the efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in the
Like
Comment
Share
